On Invalid Date, Redhill Biopharma (NASDAQ: RDHL) reported Q2 2024 earnings per share (EPS) of N/A, up N/A year over year. Total Redhill Biopharma earnings for the quarter were N/A. In the same quarter last year, Redhill Biopharma's earnings per share (EPS) was -$100.00.
As of Q3 2024, Redhill Biopharma's earnings has grown year over year. Redhill Biopharma's earnings in the past year totalled -$30.17 million.
What was RDHL's revenue last quarter?
On Invalid Date, Redhill Biopharma (NASDAQ: RDHL) reported Q2 2024 revenue of N/A up N/A year over year. In the same quarter last year, Redhill Biopharma's revenue was $1.80 million.
What was RDHL's revenue growth in the past year?
As of Q3 2024, Redhill Biopharma's revenue has grown -89.63% year over year. This is 125.22 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 35.59%. Redhill Biopharma's revenue in the past year totalled $3.71 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.